CT P63
Alternative Names: CT-P63Latest Information Update: 08 Feb 2023
At a glance
- Originator Celltrion
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 04 Sep 2022 Adverse events and pharmacokinetics data from a phase-I trial in COVID-2019 infections presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)
- 25 Jan 2022 Celltrion completes a phase I trial in COVID-2019 infections (In volunteers) in Poland (IV) (NCT05017168)
- 03 Jan 2022 Celltrion completes enrollment in a phase I trial in COVID-2019 infections (In volunteers) in Poland before January 2022